CVM

Cel-Sci Corporation

1.24 USD
-0.03 (-2.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cel-Sci Corporation stock is down -15.07% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 18.52% of the previous 26 May’s closed higher than April.

About Cel-Sci Corporation

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.